TCM
TYRA icon

TCG Crossover Management’s Tyra Biosciences TYRA Stock Holding History

TCG Crossover Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104M Hold
3,248,980
– – 2.49% 14
2026
Q1 		$124M Buy
3,248,980
+350,877
+12% +$11.4M 3.56% 7
2025
Q4 		$76.2M Hold
2,898,103
– – 2.52% 8
2025
Q3 		$40.5M Hold
2,898,103
– – 1.99% 16
2025
Q2 		$27.7M Hold
2,898,103
– – 3.17% 15
2025
Q1 		$27M Buy
2,898,103
+909,000
+46% +$11.8M 3.68% 10
2024
Q4 		$27.6M Hold
1,989,103
– – 2.7% 16
2024
Q3 		$46.8M Hold
1,989,103
– – 3.96% 10
2024
Q2 		$31.8M Hold
1,989,103
– – 3.31% 12
2024
Q1 		$32.6M Hold
1,989,103
– – 2.58% 17
2023
Q4 		$27.5M Hold
1,989,103
– – 3.06% 15
2023
Q3 		$27.4M Hold
1,989,103
– – 4.03% 13
2023
Q2 		$33.9M Hold
1,989,103
– – 5.56% 8
2023
Q1 		$32M Hold
1,989,103
– – 6.23% 5
2022
Q4 		$15.1M Buy
1,989,103
+1,043,396
+110% +$7.38M 2.67% 15
2022
Q3 		$8.31M Buy
945,707
+49,289
+5% +$451K 2.49% 13
2022
Q2 		$6.41M Hold
896,418
– – 2.72% 12
2022
Q1 		$9.59M Buy
896,418
+45,968
+5% +$546K 3.85% 9
2021
Q4 		$12M Buy
+850,450
New +$16.9M 5.6% 8

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

TCG Crossover Management's TYRA Position: Q2 2026 in Review

TCG Crossover Management held its Tyra Biosciences (TYRA) position steady in Q2 2026 at 3,248,980 shares worth $104M. The position accounts for 2.49% of the portfolio, ranked #14.

TCG Crossover Management first reported a position in TYRA in Q4 2021 and has held it in 19 quarters since. The position peaked at $124M in Q1 2026. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • TCG Crossover Management held 3,248,980 shares of Tyra Biosciences worth $104M as of Q2 2026.
  • TCG Crossover Management left its Tyra Biosciences share count unchanged in Q2 2026.
  • Tyra Biosciences made up 2.49% of TCG Crossover Management's portfolio in Q2 2026, its #14 holding.
  • TCG Crossover Management first reported a position in Tyra Biosciences in Q4 2021 and has held it in 19 quarters since.
  • TCG Crossover Management's Tyra Biosciences position peaked at $124M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.